• Alex Kentsis

  • Jul 20, 2017

Rational combination therapy for acute myeloid leukemia

Functional genomics technology has brought numerous advances to cancer biology and to the discovery of new therapeutic targets. Now, collaborative research that was carried out with many colleagues across the country identifying Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia (discussed by Ligand-induced MET signaling as targetable codependence in acute myeloid leukemia and by The haves and the have nots) has been advanced to a novel clinical trial investigating the combination of selective MET and FGFR kinase inhibitors for potential treatment of AML.